Galanin and GalR2 Receptors in Antidepressant Treatments

抗抑郁治疗中的甘丙肽和 GalR2 受体

基本信息

  • 批准号:
    7290419
  • 负责人:
  • 金额:
    $ 38.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-22 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Galanin coexists with tryptophane hydroxylase /5-HT in a majority of dorsal raphe nucleus (DRN) neurons, and the galanin receptors GalR1 and GalR2 are expressed at high concentrations in the DRN. By gene chipping analysis of 35,000 transcripts, we found that galanin is one of the 8 transcripts that are significantly elevated by at least two antidepressant treatments, fluoxetine and electroconvulsive therapy, in the rat DRN. Two components of the galaninergic system, galanin and GalR2, were altered by these antidepressant treatments: galanin mRNA levels were increased by 100 percent by both antidepressant treatments, and fluoxetine (and desipramine) treatments induced a 50 percent increase in GalR2 binding sites in the rat DRN. Activation of GalR2 promotes calcium influx, neuronal firing, and neurogenesis, while activation of GalR1 inhibits adenylyl cyclase and suppresses neuronal activity. Thus, a shift in the galaninergic transmission in the DRN towards a GalR2 mediated action following antidepressant treatments may enhance the activity of 5-HT neurons that express GalR2 and contribute to the elevation of synaptic 5-HT levels in terminal areas of these DRN neurons, such as frontal cortex and hippocampus. The functional significance of the elevated galaninergic activity in the DRN for the antidepressant effects of fluoxetine is underlined by our data that a galanin receptor antagonist, M40, blocked the antidepressant effects of fluoxetine, and two systemically active galanin receptor agonists, galnon and galmic, produced an antidepressant like effect in the forced swim test. We aim at validating the GalR2 receptor as a target for new antidepressant drugs. We will focus on the galanin-5HT interactions in the DRN and their changes during antidepressant drug treatment. Our experiments will be carried out in rats and transgenic mice strains that lack either GalR1 or GalR2. The planned work will deepen our knowledge of the galanin/5-HT system in the DRN and its contribution to the effects of antidepressant treatments.
描述(由申请人提供):甘丙肽与甘草酸羟化酶/5-HT共存于大多数中缝背核(DRN)神经元中,甘丙肽受体GalR 1和GalR 2在DRN中以高浓度表达。通过对35,000个转录本的基因芯片分析,我们发现甘丙肽是至少两种抗抑郁药治疗(氟西汀和电休克治疗)在大鼠DRN中显著升高的8个转录本之一。甘丙肽能系统的两个组成部分,甘丙肽和GalR 2,被这些抗抑郁药治疗改变:甘丙肽mRNA水平增加了100%的抗抑郁药治疗,氟西汀(和地昔帕明)治疗诱导大鼠DRN中GalR 2结合位点增加了50%。GalR 2的激活促进钙内流、神经元放电和神经发生,而GalR 1的激活抑制腺苷酸环化酶并抑制神经元活性。因此,抗抑郁药治疗后DRN中的甘丙肽能传递向GalR 2介导的作用的转变可能增强表达GalR 2的5-HT神经元的活性,并有助于这些DRN神经元的终末区域(如额叶皮质和海马)中突触5-HT水平的升高。我们的数据强调了DRN中甘丙肽能活性升高对氟西汀抗抑郁作用的功能意义,甘丙肽受体拮抗剂M40阻断了氟西汀的抗抑郁作用,两种全身活性甘丙肽受体激动剂galnon和galmic在强迫游泳试验中产生了抗抑郁样作用。我们的目标是验证GalR 2受体作为新的抗抑郁药物的靶点。我们将重点关注甘丙肽-5-羟色胺在DRN的相互作用和抗抑郁药物治疗期间的变化。我们的实验将在缺乏GalR 1或GalR 2的大鼠和转基因小鼠品系中进行。计划中的工作将加深我们对DRN中甘丙肽/5-HT系统及其对抗抑郁治疗效果的贡献的了解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAMAS BARTFAI其他文献

TAMAS BARTFAI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAMAS BARTFAI', 18)}}的其他基金

Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR1/2 激动剂来治疗神经毒气引起的癫痫发作
  • 批准号:
    7696013
  • 财政年份:
    2008
  • 资助金额:
    $ 38.36万
  • 项目类别:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR 1/2 激动剂来治疗神经毒气引起的癫痫发作
  • 批准号:
    7899875
  • 财政年份:
    2008
  • 资助金额:
    $ 38.36万
  • 项目类别:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR 1/2 激动剂来治疗神经毒气引起的癫痫发作
  • 批准号:
    7541156
  • 财政年份:
    2008
  • 资助金额:
    $ 38.36万
  • 项目类别:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR 1/2 激动剂来治疗神经毒气引起的癫痫发作
  • 批准号:
    7687924
  • 财政年份:
    2008
  • 资助金额:
    $ 38.36万
  • 项目类别:
Galanin and GalR2 Receptors in Antidepressant Treatments
抗抑郁治疗中的甘丙肽和 GalR2 受体
  • 批准号:
    7682825
  • 财政年份:
    2006
  • 资助金额:
    $ 38.36万
  • 项目类别:
Galanin and GalR2 Receptors in Antidepressant Treatments
抗抑郁治疗中的甘丙肽和 GalR2 受体
  • 批准号:
    7141865
  • 财政年份:
    2006
  • 资助金额:
    $ 38.36万
  • 项目类别:
Galanin and GalR2 Receptors in Antidepressant Treatments
抗抑郁治疗中的甘丙肽和 GalR2 受体
  • 批准号:
    7491466
  • 财政年份:
    2006
  • 资助金额:
    $ 38.36万
  • 项目类别:
Galanin and GaIR2 receptors in antidepressant treatments
抗抑郁治疗中的甘丙肽和 GaIR2 受体
  • 批准号:
    7120859
  • 财政年份:
    2005
  • 资助金额:
    $ 38.36万
  • 项目类别:
Transciption-independent Signaling by IL1 in Neurons
神经元中 IL1 的转录独立信号传导
  • 批准号:
    6878128
  • 财政年份:
    2003
  • 资助金额:
    $ 38.36万
  • 项目类别:
Transciption-independent Signaling by IL1 in Neurons
神经元中 IL1 的转录独立信号传导
  • 批准号:
    6700317
  • 财政年份:
    2003
  • 资助金额:
    $ 38.36万
  • 项目类别:

相似海外基金

Neuroendocrine regulation of energy metabolism: role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the thermoregulatory cascade
能量代谢的神经内分泌调节:垂体腺苷酸环化酶激活多肽(PACAP)在温度调节级联中的作用
  • 批准号:
    RGPIN-2021-04040
  • 财政年份:
    2022
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Discovery Grants Program - Individual
Controlled Release of Pituitary Adenylate Cyclase Activating Polypeptide from a Hydrogel-Nanoparticle Delivery Vehicle for Applications in the Central Nervous System
从水凝胶-纳米粒子递送载体中控制释放垂体腺苷酸环化酶激活多肽,用于中枢神经系统的应用
  • 批准号:
    547124-2020
  • 财政年份:
    2022
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Controlled Release of Pituitary Adenylate Cyclase Activating Polypeptide from a Hydrogel-Nanoparticle Delivery Vehicle for Applications in the Central Nervous System
从水凝胶-纳米粒子递送载体中控制释放垂体腺苷酸环化酶激活多肽,用于中枢神经系统的应用
  • 批准号:
    547124-2020
  • 财政年份:
    2021
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Neuroendocrine regulation of energy metabolism: role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the thermoregulatory cascade
能量代谢的神经内分泌调节:垂体腺苷酸环化酶激活多肽(PACAP)在温度调节级联中的作用
  • 批准号:
    RGPIN-2021-04040
  • 财政年份:
    2021
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Discovery Grants Program - Individual
The Molecular Mechanism of the Secretion of the Bacterial Toxin Adenylate Cyclase
细菌毒素腺苷酸环化酶分泌的分子机制
  • 批准号:
    451966
  • 财政年份:
    2021
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Operating Grants
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10455587
  • 财政年份:
    2020
  • 资助金额:
    $ 38.36万
  • 项目类别:
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10261394
  • 财政年份:
    2020
  • 资助金额:
    $ 38.36万
  • 项目类别:
Diagnosis and therapeutic effect of neurally mediated syncope (NMS) using fluctuation of adenylate cyclase activity
利用腺苷酸环化酶活性波动对神经介导性晕厥(NMS)的诊断和治疗效果
  • 批准号:
    20K08498
  • 财政年份:
    2020
  • 资助金额:
    $ 38.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pituitary adenylate cyclase-activating polypeptide 27 in the paraventricular thalamus and its projections: Role in ethanol drinking
室旁丘脑中的垂体腺苷酸环化酶激活多肽 27 及其预测:在乙醇饮用中的作用
  • 批准号:
    10380126
  • 财政年份:
    2020
  • 资助金额:
    $ 38.36万
  • 项目类别:
The role of prefrontostriatal Pituitary Adenylate Cyclase Activating Polypeptide in excessive and compulsive ethanol drinking
前额纹状体垂体腺苷酸环化酶激活多肽在过量和强迫性乙醇饮酒中的作用
  • 批准号:
    10662279
  • 财政年份:
    2020
  • 资助金额:
    $ 38.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了